Longdom Conferences

Speaker

Apr 19-20, 2022    Tokyo, Japan
2nd International Conference on

Clinical and Medical Oncology

Tamar Safra
1

Tamar Safra

Tel Aviv University, Israel Israel

Title: Cancer & Oncology

Abstract:

Introduction: Ovarian cancer (OC) is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death worldwide. Since 2014 Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) play a pivotal role in the management of OC in the adjuvant and recurrence setting. In recent years the rise in access and availability of medical cannabis among cancer patients has resulted in its’ integration as a mainstay of supportive care. Pre-clinical studies demonstrated immunomodulatory and epigenetic properties of cannabis. Therefore, cannabis may induce epigenetic modifications, potentially interfering with the beneficial clinical effect of PARPi therapy. We aimed to study whether cannabis affect oncological outcomes among OC patients treated with PARPi in the adjuvant and recurrent setting.

Methods: We conducted a retrospective analysis of 93 OC consecutive patients with germline, somatic or wild type (WT) BRCA mutation, treated at the Tel Aviv Sourasky Medical Center (TASMC) with PARPi. Majority of patients received PARPi for recurrent disease n=68 39 (73.11%). Cannabis was administered either by smoking, nebulizer, oil or combination. We compared oncological outcomes of patient treated with maintenance PARPi and patients treated with maintenance PARPi and cannabis. We evaluated progression free survival (PFS), overall survival (OS) and duration of response on maintenance PARPi’s therapy (DOR).

Results: Among 93 patients treated with PARPi, 29 (31.18%) women used simultaneously cannabis during the same period (cannabis group). Median PFS was 21.03 months in the PARPi group, and 20.04 months in the cannabis group (P=.77). However, median OS in patients receiving PARPi in the recurrent setting was longer in the cannabis group compared to PARPi only group 129.28 Vs 99.02 months, respectively (P=.03). The median time on PARPi therapy was similar in both groups, 9.5 months in the PARPi only group and 12.11 months in the cannabis group (P=.894).

Conclusion: The use of supportive cannabis during PARPi treatment did not compromise OS, PFS or DOR on maintenence PARPi therapy. Considering the limitations of this work, further larger prospective clinical studies are warrented.

Biography:

Tamar Safra is from Tel Aviv University, Tel Aviv, Israel completed his work on The effect of cannabis use on oncological outcomes in ovarian cancer patients treated with PARP inhibitors.

Useful Links

News

AMU VC Inaugurates Oral Oncology Unit

2021-07-19 - 2021-07

Aligarh: To mark the Silver Jubilee of Dr Ziauddin Ahmad Dental College (AMU), the Oral Oncology Unit has been established in the Department of Oral and Maxillofacial Surgery and was inaugurated by the Vice Chancellor, Prof Tariq Mansoor. The Vice Chancellor also released the first issue of the University Journal of Maxillofacial Surgery and Oral Sciences on the occasion. Prof Mansoor appreciated the establishment of the oral oncology unit and highlighted the need of involvement of an interdisciplinary surgical team for best outcome of the oral cancer treatment. He assured his full cooperation for further development of the Dental College and praised the team of University Journal of Maxillofacial Surgery for publishing the good quality papers in the first issue. On the occasion Prof Shahid A Siddiqui (Dean, Principal and CMS, JN Medical College), appreciated the establishment of Oral Oncology Unit and highlighted the incidence of oral cancer. He mentioned that the facilities of treating oral cancer with resection and rehabilitation are available at a few centres and it is very expensive too. There is a need to reduce the treatment cost to improve the affordability of treatment to the common man, he added.

Your Cancer Answers: What is a breast surgical oncologist?

2021-07-22 - 2021-07

A breast surgical oncologist is a surgeon who specializes in breast cancer and other diseases of the breast. Mission Hope Cancer Center is proud to have Colleen O’Kelly Priddy, MD, join our team as our Breast Surgical Oncologist. Dr. O’Kelly is Board Certified in Surgery and subspecialized in Breast Surgical Oncology. She joins a caring, compassionate team that has dedicated their time and knowledge to serve the community members that may be faced with abnormalities of the breast. When faced with breast cancer, a surgical oncologist is trained to treat cancer by removing cancerous tissues and surgical management of tumors. Breast surgeons specialize in the evaluation, diagnosis, treatment, and management of conditions in which patients experience masses, lumps, infection, and pain in the breasts. Breast specialists are highly skilled in their field because they have dedicated their practice to a smaller scope and have completed specialty-specific training called fellowships. The formal training provided by the fellowship ensures that each fellow who graduated is exposed to multidisciplinary aspects of care and advanced research and techniques. With years of training and years of education focused on breast disease, they have an in-depth knowledge of cancer biology, genetics, and the most advanced surgical options to help patients achieve the best possible results and can provide novel and innovative treatments for breast cancer patients.

Newsletter

© 2024 All Rights Reserved by Longdom